Thank you for taking the trouble to respond it all makes for better understanding and accuracy. When wrong I am happy to be corrected.
CLTann
An interesting response I agree from Dr Martin. I will try and find the origiinal trial.
Al from Canada.
Great links.
This is an interesting trial from that group. Complex as usual. There is a suggestion that 20HEI is increased and it is an antagonist for breast cancer if I read this properly, so the phyto oestrogenic effect might be benificial?
It is a bit above me. Maybe you could show it to your oncologist and come back?.
http://www.ajcn.org/cgi/content/full/79/2/318
......"This leads to the formation of the 2 major metabolites of estradiol, 2-hydroxyestrone (2OHE1) and 16{alpha}-hydroxyestrone (16{alpha}OHE1) (13), which are excreted in either the urine or the feces (14) and have distinct biological properties. Although hydroxylation of estradiol and estrone can also occur at multiple sites (carbons 1, 2, 4, 6, 7, 11, and 14-18), the 2- and 16{alpha}-hydroxylated metabolites are the most abundant (15)........
2OHE1 has shown little biological activity, with some antiestrogenic action in vitro (16-18). Conversely, 16{alpha}OHE1 has shown estrogen agonistic activity, including increased cell proliferation of human breast cancer cell lines in vitro (17-19), and an uterotropic effect comparable with that of estrogen in vivo (20, 21). Therefore, persons who have an increased proportion of 16{alpha}-hydroxylation (a low ratio of 2OHE1 to 16{alpha}OHE1) are suggested to have an increased risk of breast cancer (17, 22, 23).
"Supplementation with flaxseed but not soy or placebo significantly increased urinary 2OHE1 concentrations (7.25 ± 1.48, 6.15 ± 0.97, and 11.36 ± 1.93 µg/24 h in the placebo, soy, and flaxseed groups, respectively). No significant differences in 16{alpha}OHE1 concentrations after 16 wk were observed in any of the treatment groups (6.87 ± 1.32, 6.24 ± 1.05, and 5.07 ± 0.79 µg/24 h in the placebo, soy, and flaxseed groups, respectively).".......
RB